DeepMed Research

Peking University First Hospital (Peking Univesity First Medical School)

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery

Phase 2

Not yet recruiting

Conditions: Upper Urinary Tract Urothelial Carcinoma

Interventions: Other: Standard of Care
Drug: Disitamab Vedotin
Radiation: Radiotherapy

First Posted Date: 2024-01-18

Last Posted Date: 2024-01-18

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 60

Registration Number: NCT06210490

A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With RIMM

Not Applicable

Recruiting

Conditions: Renal Injury
Multiple Myeloma

Interventions: Drug: Bortezomib

First Posted Date: 2024-01-12

Last Posted Date: 2024-01-12

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 30

Registration Number: NCT06203145

Locations: 🇨🇳
Peking University First Hospital, Beijing, Beijing, China

Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC

Recruiting

Conditions: Urothelial Carcinoma

Interventions: Radiation: Radiotherapy
Drug: Chemotherapy
Drug: Immunotherapy

First Posted Date: 2023-11-07

Last Posted Date: 2024-07-25

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 178

Registration Number: NCT06120374

Locations: 🇨🇳
Department of Radiotherapy Oncology, Peking University First Hospital, Beijing, China
🇨🇳
Department of Medical Oncology, Peking University First Hospital, Beijing, China
🇨🇳
Departmeng of Urology, Peking University First Hospital, Beijing, China

Evaluate the Accuracy of a COPD Screening Algorithm Model

Completed

Conditions: COPD

First Posted Date: 2023-10-31

Last Posted Date: 2024-01-23

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 400

Registration Number: NCT06109974

Locations: 🇨🇳
The Hospital of Changping District Beijing, Beijing, Beijing, China
🇨🇳
Guangfa Wang, Beijing, Beijing, China
🇨🇳
Shichahai community health service center, Beijing, Beijing, China

and more 2 locations

Heart Failure Treatment Pattern Analysis of HF Patients in HF Centers and Non-HF Centers in China

Completed

Conditions: Heart Failure

Interventions: Other: no intervention

First Posted Date: 2023-10-25

Last Posted Date: 2024-01-23

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 22500

Registration Number: NCT06099028

Locations: 🇨🇳
Department of Cardiology, Peking University First Hospital, Beijing, China

Different Dose Esketamine and Dexmedetomidine for Supplemental Analgesia and Longterm Outcomes

Phase 4

Not yet recruiting

Conditions: Scoliosis Correction
Esketamine
Postoperative Analgesia
Dexmedetomidine
Chronic Postsurgical Pain

Interventions: Drug: Esketamine

First Posted Date: 2023-10-17

Last Posted Date: 2023-10-19

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 312

Registration Number: NCT06087510

Locations: 🇨🇳
Beijing University First Hospital, Beijing, Beijing, China

Different Dose Esketamine and Dexmedetomidine Combination for Supplemental Analgesia After Scoliosis Correction Surgery

Phase 4

Not yet recruiting

Conditions: Scoliosis Correction
Chronic Postsurgical Pain
Esketamine
Dexmedetomidine
Postoperative Analgesia

Interventions: Drug: Esketamine

First Posted Date: 2023-10-02

Last Posted Date: 2023-10-04

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 312

Registration Number: NCT06062550

Locations: 🇨🇳
Beijing University First Hospital, Beijing, Beijing, China

Perioperative Dexmedetomidine and Long-term Survival After Cancer Surgery

Not Applicable

Recruiting

Conditions: Elderly
Cancer Surgery
Dexmedetomidine
Long-Term Survivors

Interventions: Drug: Placebo
Drug: Dexmedetomidine

First Posted Date: 2023-09-11

Last Posted Date: 2023-12-29

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 4532

Registration Number: NCT06030804

Locations: 🇨🇳
Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
🇨🇳
The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China
🇨🇳
The First Affiliated Hospital of China University of Science and Technology(Anhui Provincial Hospital), Hefei, Hebei, China

and more 31 locations

A Phase II Neoadjuvant Study of Darolutamide Plus ADT in Men With Localized Prostate Cancer

Phase 2

Recruiting

Conditions: Prostate Cancer

Interventions: Drug: Darolutamide+ADT

First Posted Date: 2023-09-08

Last Posted Date: 2023-12-12

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 53

Registration Number: NCT06029036

Locations: 🇨🇳
Peking University First Hospital, Beijing, China

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

Phase 2

Not yet recruiting

Conditions: Recurrent Non-Squamous Non-Small Cell Lung Cancer
Advanced Non-squamous Non-small-cell Lung Cancer
Metastatic Non-squamous Non Small Cell Lung Cancer

Interventions: Drug: pembrolizumab
Drug: lenvatinib
Drug: albumin-bound paclitaxel

First Posted Date: 2023-09-08

Last Posted Date: 2023-09-13

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 28

Registration Number: NCT06028633

Locations: 🇨🇳
Peking University First Hospital Ethics Committee, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy